635 related articles for article (PubMed ID: 16467864)
1. Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations.
Niimi H; Harada H; Harada Y; Ding Y; Imagawa J; Inaba T; Kyo T; Kimura A
Leukemia; 2006 Apr; 20(4):635-44. PubMed ID: 16467864
[TBL] [Abstract][Full Text] [Related]
2. Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations.
Harada Y; Harada H
J Cell Physiol; 2009 Jul; 220(1):16-20. PubMed ID: 19334039
[TBL] [Abstract][Full Text] [Related]
3. Molecular mechanisms that produce secondary MDS/AML by RUNX1/AML1 point mutations.
Harada Y; Harada H
J Cell Biochem; 2011 Feb; 112(2):425-32. PubMed ID: 21268063
[TBL] [Abstract][Full Text] [Related]
4. Mutations of genes in the receptor tyrosine kinase (RTK)/RAS-BRAF signal transduction pathway in therapy-related myelodysplasia and acute myeloid leukemia.
Christiansen DH; Andersen MK; Desta F; Pedersen-Bjergaard J
Leukemia; 2005 Dec; 19(12):2232-40. PubMed ID: 16281072
[TBL] [Abstract][Full Text] [Related]
5. AML1/RUNX1 gene point mutations in childhood myeloid malignancies.
Migas A; Savva N; Mishkova O; Aleinikova OV
Pediatr Blood Cancer; 2011 Oct; 57(4):583-7. PubMed ID: 21294243
[TBL] [Abstract][Full Text] [Related]
6. Point mutations in the AML1/RUNX1 gene associated with myelodysplastic syndrome.
Harada H; Harada Y
Crit Rev Eukaryot Gene Expr; 2005; 15(3):183-96. PubMed ID: 16390315
[TBL] [Abstract][Full Text] [Related]
7. Cooperation of activating Ras/rtk signal transduction pathway mutations and inactivating myeloid differentiation gene mutations in M0 AML: a study of 45 patients.
Roumier C; Lejeune-Dumoulin S; Renneville A; Goethgeluck AS; Philippe N; Fenaux P; Preudhomme C
Leukemia; 2006 Mar; 20(3):433-6. PubMed ID: 16424869
[TBL] [Abstract][Full Text] [Related]
8. Implications of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome (MDS): future molecular therapeutic directions for MDS.
Harada H; Harada Y; Kimura A
Curr Cancer Drug Targets; 2006 Sep; 6(6):553-65. PubMed ID: 17017876
[TBL] [Abstract][Full Text] [Related]
9. Novel loss-of-function mutations of the haematopoiesis-related transcription factor, acute myeloid leukaemia 1/runt-related transcription factor 1, detected in acute myeloblastic leukaemia and myelodysplastic syndrome.
Nakao M; Horiike S; Fukushima-Nakase Y; Nishimura M; Fujita Y; Taniwaki M; Okuda T
Br J Haematol; 2004 Jun; 125(6):709-19. PubMed ID: 15180860
[TBL] [Abstract][Full Text] [Related]
10. High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia.
Harada H; Harada Y; Niimi H; Kyo T; Kimura A; Inaba T
Blood; 2004 Mar; 103(6):2316-24. PubMed ID: 14615365
[TBL] [Abstract][Full Text] [Related]
11. Genetics of therapy-related myelodysplasia and acute myeloid leukemia.
Pedersen-Bjergaard J; Andersen MK; Andersen MT; Christiansen DH
Leukemia; 2008 Feb; 22(2):240-8. PubMed ID: 18200041
[TBL] [Abstract][Full Text] [Related]
12. [Distinct genetic pathway in the molecular pathogenesis of MDS/AML with AML1/RUNX1 point mutations].
Harada H
Rinsho Ketsueki; 2007 Jul; 48(7):541-6. PubMed ID: 17695302
[No Abstract] [Full Text] [Related]
13. Mutations of the PTPN11 gene in therapy-related MDS and AML with rare balanced chromosome translocations.
Christiansen DH; Desta F; Andersen MK; Pedersen-Bjergaard J
Genes Chromosomes Cancer; 2007 Jun; 46(6):517-21. PubMed ID: 17330262
[TBL] [Abstract][Full Text] [Related]
14. [Radiation associated leukemia and myelodysplastic syndrome].
Kimura A
Nihon Rinsho; 2012 Mar; 70(3):431-5. PubMed ID: 22514921
[TBL] [Abstract][Full Text] [Related]
15. RUNX1 gene mutation in primary myelodysplastic syndrome--the mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome.
Chen CY; Lin LI; Tang JL; Ko BS; Tsay W; Chou WC; Yao M; Wu SJ; Tseng MH; Tien HF
Br J Haematol; 2007 Nov; 139(3):405-14. PubMed ID: 17910630
[TBL] [Abstract][Full Text] [Related]
16. Somatic point mutations in RUNX1/CBFA2/AML1 are common in high-risk myelodysplastic syndrome, but not in myelofibrosis with myeloid metaplasia.
Steensma DP; Gibbons RJ; Mesa RA; Tefferi A; Higgs DR
Eur J Haematol; 2005 Jan; 74(1):47-53. PubMed ID: 15613106
[TBL] [Abstract][Full Text] [Related]
17. Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia.
Shih LY; Huang CF; Wang PN; Wu JH; Lin TL; Dunn P; Kuo MC
Leukemia; 2004 Mar; 18(3):466-75. PubMed ID: 14737077
[TBL] [Abstract][Full Text] [Related]
18. Cytogenetic evolution following the transformation of myelodysplastic syndrome to acute myelogenous leukemia: implications on the overlap between the two diseases.
Ghaddar HM; Stass SA; Pierce S; Estey EH
Leukemia; 1994 Oct; 8(10):1649-53. PubMed ID: 7934160
[TBL] [Abstract][Full Text] [Related]
19. New mechanisms of AML1 gene alteration in hematological malignancies.
Roumier C; Fenaux P; Lafage M; Imbert M; Eclache V; Preudhomme C
Leukemia; 2003 Jan; 17(1):9-16. PubMed ID: 12529654
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive analysis of cooperative gene mutations between class I and class II in de novo acute myeloid leukemia.
Ishikawa Y; Kiyoi H; Tsujimura A; Miyawaki S; Miyazaki Y; Kuriyama K; Tomonaga M; Naoe T
Eur J Haematol; 2009 Aug; 83(2):90-8. PubMed ID: 19309322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]